Intellia presents positive results from the Phase 2 Study of NTLA-2002, an investigational in vivo crispr gene editing treatment for hereditary...

Repare Therapeutics Inc., a leading clinical─stage precision oncology company, presented updated data highlighting the benefits of its...

A new study from the MD Anderson Cancer Center reveals that quitting smoking within six months of a cancer diagnosis can significantly improve...

HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company’s...

Drugs aimed at HER2-positive breast cancer may also help certain patients with bile duct cancer, as indicated by findings from a patient trial that...

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with...

New study reveals how ovarian cancer shields itself from the immune system, opening doors to innovative immunotherapy methods for more effective...

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus...

New Found Gold (TSXV:NFG) reveals Phase II metallurgical testing program at its Queensway Project in Newfoundland.

Learn how a gene signature technique personalizes chemotherapy for early triple-negative breast cancer, improving disease-free survival rates